Patents by Inventor Ming-Cheng Wei
Ming-Cheng Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240135990Abstract: A resistive memory apparatus including a memory cell array, at least one dummy transistor and a control circuit is provided. The memory cell array includes a plurality of memory cells. Each of the memory cells includes a resistive switching element. The dummy transistor is electrically isolated from the resistive switching element. The control circuit is coupled to the memory cell array and the dummy transistor. The control circuit is configured to provide a first bit line voltage, a source line voltage and a word line voltage to the dummy transistor to drive the dummy transistor to output a saturation current. The control circuit is further configured to determine a value of a second bit line voltage for driving the memory cells according to the saturation current. In addition, an operating method and a memory cell array of the resistive memory apparatus are also provided.Type: ApplicationFiled: December 28, 2023Publication date: April 25, 2024Applicant: Winbond Electronics Corp.Inventors: Ming-Che Lin, Min-Chih Wei, Ping-Kun Wang, Yu-Ting Chen, Chih-Cheng Fu, Chang-Tsung Pai
-
Patent number: 11931456Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.Type: GrantFiled: November 16, 2022Date of Patent: March 19, 2024Assignee: MegaPro Biomedical Co. Ltd.Inventors: Ming-Cheng Wei, Yuan-Hung Hsu, Wen-Yuan Hsieh, Chia-Wen Huang, Chih-Lung Chen, Jhih-Yun Jian, Shian-Jy Wang
-
Publication number: 20230078391Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.Type: ApplicationFiled: November 16, 2022Publication date: March 16, 2023Inventors: Ming-Cheng Wei, Yuan-Hung Hsu, Wen-Yuan Hsieh, Chia-Wen Huang, Chih-Lung Chen, Jhih-Yun Jian, Shian-Jy Wang
-
Patent number: 11541007Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.Type: GrantFiled: May 16, 2019Date of Patent: January 3, 2023Assignee: MegaPro Biomedical Co., Ltd.Inventors: Ming-Cheng Wei, Yuan-Hung Hsu, Wen-Yuan Hsieh, Chia-Wen Huang, Chih-Lung Chen, Jhih-Yun Jian, Shian-Jy Wang
-
Publication number: 20220080057Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.Type: ApplicationFiled: November 24, 2021Publication date: March 17, 2022Inventors: Wen-Yuan Hsieh, Yuan-Hung Hsu, Chia-Wen Huang, Ming-Cheng Wei, Chih-Lung Chen, Shian-Jy Wang
-
Publication number: 20200360287Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.Type: ApplicationFiled: May 16, 2019Publication date: November 19, 2020Inventors: Ming-Cheng Wei, Yuan-Hung Hsu, Wen-Yuan Hsieh, Chia-Wen Huang, Chih-Lung Chen, Jhih-Yun Jian, Shian-Jy Wang
-
Patent number: 10632081Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.Type: GrantFiled: April 29, 2016Date of Patent: April 28, 2020Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Chih-Peng Liu, Ya-Chin Lo, Ming-Cheng Wei, Maggie Lu, Shuen-Hsiang Chou, Shih-Ta Chen, Hsiang-Wen Tseng
-
Publication number: 20190247522Abstract: A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.Type: ApplicationFiled: November 29, 2018Publication date: August 15, 2019Inventors: Wen-Yuan Hsieh, Yuan-Hung Hsu, Chia-Wen Huang, Ming-Cheng Wei, Chih-Lung Chen, Shian-Jy Wang
-
Patent number: 9833464Abstract: The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors.Type: GrantFiled: December 29, 2010Date of Patent: December 5, 2017Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: In San Kim, Byung Heon Lee, Maggie J M Lu, Hsiang-Fa Liang, Yi-ju Ko, Ya-Chin Lo, Li-Wen Chang, Ming-Cheng Wei
-
Publication number: 20160361268Abstract: Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C4-C20 alkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C4-C20 alkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.Type: ApplicationFiled: April 29, 2016Publication date: December 15, 2016Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Chih-Peng LIU, Ya-Chin LO, Ming-Cheng WEI, Maggie LU, Shuen-Hsiang CHOU, Shih-Ta CHEN, Hsiang-Wen TSENG
-
Patent number: 9480712Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.Type: GrantFiled: October 14, 2014Date of Patent: November 1, 2016Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Ya-Chin Lo, Hsiang-Fa Liang, Ming-Cheng Wei, Maggie J. M. Lu, Min-Ying Lin, Chih-Peng Liu, Chun-Min Liu, Hsiang-Wen Tseng, Tse-Min Teng, Jui-Hsiang Chen, Yi-Man Chou, Yi-Ting Hsieh, Chia-Mu Tu
-
Publication number: 20150118322Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.Type: ApplicationFiled: October 14, 2014Publication date: April 30, 2015Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Ya-Chin LO, Hsiang-Fa LIANG, Ming-Cheng WEI, Maggie J.M. LU, Min-Ying LIN, Chih-Peng LIU, Chun-MIN LIU, Hsiang-Wen TSENG, Tse-Min TENG, Jui-Hsiang CHEN, Yi-Man CHOU, Yi-Ting HSIEH, Chia-Mu TU
-
Publication number: 20140199349Abstract: Disclosed is a pH-sensitive hyaluronic acid derivative, comprising at least one repeat unit as shown in the following formula (I), wherein HA represents a unit comprising N-acetyl-D-glucosamine and D-glucuronic acid, q represents an integer of 2 to 10,000; A represents a biocleavable linkage comprising at least one of hydrazone, acetal, ketal and imine; M represents at least one of a hydrophobic fragment, a hydrophilic fragment, and an amphiphilic fragment, and p represents the number of [A-M] directly grafted onto each HA unit, p represents an integer of 0 to 4, and the p of each HA unit is not 0 at the same time.Type: ApplicationFiled: December 29, 2011Publication date: July 17, 2014Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jean-Dean Yang, Ayi-Man Chou, Jui-Hsiang Chen, Hsia-Wei Liu, Shian-Jy Wang, Tse-Min Teng, Hsiang-Fa Liang, Ming-Cheng Wei, Maggie J.M. Lu
-
Publication number: 20120294931Abstract: The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors.Type: ApplicationFiled: December 29, 2010Publication date: November 22, 2012Applicants: Kyungpook National University Industry-Academic Cooperation Foundation, INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: In San Kim, Byung Heon Lee, Maggie JM Lu, Hsiang-Fa Liang, Yi-ju Ko, Ya-Chin Lo, Li-Wen Chang, Ming-Cheng Wei